Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 2307 Download: 136 Crossref: 2

Review

Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis

Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(3):303-325. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0022

View: 2962 Download: 250 Web of Science: 1 Crossref: 2

Snapshot

Immunopathogenesis of liver fibrosis in steatotic liver disease

Chaerin Woo, Won-Il Jeong

Clin Mol Hepatol. 2024;30(2):299-302. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0113

View: 2474 Download: 100

Review

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 6022 Download: 285 Web of Science: 8 Crossref: 10

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 4571 Download: 318 Web of Science: 17 Crossref: 17

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4480 Download: 228 Web of Science: 20 Crossref: 19

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 5326 Download: 246 Web of Science: 14 Crossref: 16

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 7779 Download: 521 Web of Science: 48 Crossref: 54

Correspondence

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 2182 Download: 48

Original Article

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(3):705-720. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0004

View: 4686 Download: 250 Web of Science: 18 Crossref: 22

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 4057 Download: 202 Web of Science: 13 Crossref: 16

Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions

Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun

Clin Mol Hepatol. 2023;29(2):465-481. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0327

View: 5749 Download: 264 Web of Science: 8 Crossref: 11

Editorial

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2935 Download: 70 Web of Science: 3 Crossref: 3

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 3331 Download: 135 Web of Science: 1 Crossref: 1

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 2959 Download: 88 Web of Science: 1

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054 Correction in: Clin Mol Hepatol 2023;29(3):828

View: 2776 Download: 68 Web of Science: 3 Crossref: 2

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 10656 Download: 693 Web of Science: 51 Crossref: 55

Original Article

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 7554 Download: 402 Web of Science: 19 Crossref: 20

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 2702 Download: 72

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 5379 Download: 359 Web of Science: 10 Crossref: 10

Original Article

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2022;28(1):77-90. Published online November 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0188

View: 6231 Download: 149 Web of Science: 17 Crossref: 16

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(3):499-509. Published online February 26, 2021

DOI: https://doi.org/10.3350/cmh.2020.0333

View: 5154 Download: 138 Web of Science: 14 Crossref: 14

Review

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada

Clin Mol Hepatol. 2021;27(3):413-424. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0187

View: 14531 Download: 484 Web of Science: 26 Crossref: 28

Original Article

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0216

View: 5758 Download: 211 Web of Science: 18 Crossref: 21

Editorial

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

DOI: https://doi.org/10.3350/cmh.2021.0019

View: 4748 Download: 139 Web of Science: 5 Crossref: 6

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2021;27(1):94-96. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0305

View: 4674 Download: 144 Web of Science: 7 Crossref: 7

Review

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

Gwyneth Soon, Aileen Wee

Clin Mol Hepatol. 2021;27(1):44-57. Published online November 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0181

View: 13220 Download: 368 Web of Science: 36 Crossref: 38

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Emerging medical therapies for severe alcoholic hepatitis

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0145

View: 6520 Download: 227 Web of Science: 16 Crossref: 17

Review

Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis

Le Thi Thanh Thuy, Hoang Hai, Norifumi Kawada

Clin Mol Hepatol. 2020;26(3):280-293. Published online June 4, 2020

DOI: https://doi.org/10.3350/cmh.2020.0037

View: 8019 Download: 237 Web of Science: 14 Crossref: 15

Original Article

Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients

Waleed Seif Eldin Mohamed Mostafa, Mohammed Hassan Saiem Al-Dahr, Dalia Abdel Hamid Omran, Zeinab Fathy Abdullah, Suzan Hamdy Elmasry, Mohamed Nabil Ibrahim

Clin Mol Hepatol. 2020;26(1):60-69. Published online October 22, 2019

DOI: https://doi.org/10.3350/cmh.2019.0051

View: 6443 Download: 140 Web of Science: 4 Crossref: 4

1 | 2 | 3 |

Viewed By 6029	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5560	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 5357	MAFLD: How is it different from NAFLD?
Viewed By 5326	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4904	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 208	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 146	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 109	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search